Fosun International 2011 Annual Result Presentation April 2012
FOSUN TIMES 2013.4.30 … · 2013-05-09 · Senior Vice President of Fosun Pharma. Wanbang Pharma...
Transcript of FOSUN TIMES 2013.4.30 … · 2013-05-09 · Senior Vice President of Fosun Pharma. Wanbang Pharma...
FOSUN TIMES 2013.4.30
News
04
By�Yi�Jinyuan
■ FOSUN�TIMES�Subsequent�to�
its� listing� in� Hong� Kong,� Fosun�
Pharma� strategically� became�
more� focused�on�development� in�
pharmaceutical� manufacturing�
with� a� strategic� development�
model�of�“internal�growth,�exter-
nal� expansion� and� integrated� de-
velopment”.
Recently,�Fosun�Pharma�ac-
celerated� integration� of� strategic�
cardiovascular� product� supply�
chains.�Wanbang�Pharma,�one�of�
its�subsidiaries,�acquired�51%�eq-
uity� of� Zaozhuang� Sainuokang�
and� actively� engaged� in� interna-
tional� development� through� co-
operation�with� the�German� com-
pany�Biotest�and�the�US�company�
Saladax,� by� which� expanded� a-
gain� cooperation� models� with�
outstanding� overseas� pharmaceu-
tical� firms� and� comprehensively�
enhanced� competitiveness� in� the�
industry.
As�a�major�subsidiary�of�Fo-
sun� Pharma,� Wanbang� Pharma�
adhered�to�a�developmental�strat-
egy�of�“dual�directions�from�one�
centre” in� positioning� itself,�
meaning� centering� around� dia-
betes�medicines�while� expanding�
into� cardiovascular� and� anti-can-
cer�medicines.�Wanbang� Pharma�
is� the� largest� sodium� heparin� in-
jection� manufacturer� in� China�
and� a� leading� low� molecular�
weight� heparin� injection� manu-
facturer�in�the�country.�Heparin�is�
a� substance� extracted� from�
porcine� small� intestinal� mucus�
possessing� anticoagulant� effect�
and� is�widely� used� in� preventing�
and�treating�various�diseases,�It�is�
a� bio-medicine� with� the� largest�
sales�across�the�world�and�an�an-
ticoagulant�the�most�used.�In�Chi-
na,�a�country�accounting�for�most�
of� the� manufacture� and� exporta-
tion� of� its� raw�material,� it� occu-
pies� an� important� position� in�
medicine�export.
Sainuokang� Biochemical,� a�
company� specialized� in� produc-
tion�of�heparin�API,�has�a�leading�
position� in� China� with� its� new�
method,�technology�and�cost�con-
trol.�“Through� strategic� coopera-
tion� with� Ruicheng,� Wanbang�
Pharma� obtained� control� over�
Sainuokang�Biochemical,�thereby�
ensuring�stable�supply�of� sodium�
heparin� API� and� lowered� pur-
chase� cost� of� API.” Li� Xianlin,�
Senior� Vice� President� of� Fosun�
Pharma.
Wanbang� Pharma� also� en-
tered� into� an� agreement�with� the�
German� company� Biotest� in�
Shanghai� recently.� A� product� of�
Biotest,� is�exclusively�distributed�
by�Wanbang�Pharma�in�the�Main-
land� China� region.� Sales� of� hu-
man� serum� albumin� of� Chinese�
hospital�market� amounted� to� ap-
proximately� RMB3.5� billion� in�
2011.
Human�serum�albumin�is�an�
albumin�medicine�extracted�from�
blood� of� healthy� human,� mainly�
used�in�treatment�of�bleeding�and�
wound,� shock� caused� by� burns,�
high� intracranial� pressure� caused�
by�cerebral�edema�or�injury,�ede-
ma�or� ascites� caused� by� cirrhosis�
and�kidney�disease,�and�is�widely�
used�in�clinical�emergency.�In�re-
cent�years,�demand�of�it�increased�
in� the� market� of� China,� where�
there� were� shortages� of� related�
products�in�times.�Biotest,�a�glob-
ally� leading� company� of� blood�
and�bio-product� research�and�de-
velopment� and�manufacture,�was�
founded� in� 1946,� has� been� listed�
on� Frankfurt� Stock� Exchange�
since� 1987� and� was� included� in�
Deutsche� B觟rse� SDAX� index� in�
2007.� The� company� possesses�
outstanding� techniques� in� maxi-
mizing� separation� and� purifica-
tion� of� high-value� medicinal� in-
gredients,� where� the� techniques�
are�those�of�high�standards�in�col-
lection,� testing� and� manufactur-
ing�of�plasma�to�ensure�stable�and�
reliable�quality.�This�cooperation�
will�contribute�to�alleviating�tight�
supply� of� human� serum� albumin�
in� the�market� of� China� and� pro-
duce�a�great�social�effect.
In� addition,� Fosun� Pharma�
announced� its� entering� into� a� se-
ries� of� cooperative� agreements�
with� the� US� company� Saladax�
Biomedical,� Inc.� to� subscribe� for�
batch�D�of�additional�preferential�
shares�of�Saladax�at� a� considera-
tion� of� approximately� USD22.5�
million.�Upon�completion�of�such�
subscription,� Fosun� Pharma� will�
be� the� sole� majority� shareholder�
thereof.� Also,� Shanghai� Fosun�
Long�March�Medical�Science�Co.
,�Ltd,�a�subsidiary�of�Fosun�Phar-
ma,�entered�into�a�strategic�coop-
erative� agreement� with� Saladax,�
thereby�obtained�exclusive�distri-
bution� right� and� product� manu-
facture�right�within�China.
Saladax� possesses� advanced�
testing� technology� and�
chemotherapy�medicine�monitor-
ing�product�portfolio.�Such�coop-
eration� will� effectively� enhance�
innovative� capability� of� Fosun�
Pharma�in�medical�diagnosis�and�
enable� development� of� a� bio-test�
platform� in� China,� and� even� the�
international� market,� capable� of�
testing� concentration� and� other�
parameters� of� chemotherapy�
medicines�so�as�to�better�analysis�
effect�of�such�medicines� in� treat-
ments.� It� is� expected� that� such�
product�line�will�obtain�consider-
able�sales�scale�in�China.■
PFL Sales Office in Jiujiang Road Opened for Business
By�Flora�Shao
■ FOSUN� TIMES� [April� 16,�
2013�Shanghai]�Pramerica�Fosun�
Life� Insurance� (PFL)� staged� a�
grand� opening� ceremony� for� the�
Jiujiang�Road�Sales�Office� in� the�
Financial� Plaza,� Huangpu� Dis-
trict.� Shareholder/Prudential� rep-
resentatives� Bob� Fallon,� Senior�
Vice�President,�Bartholomew�Ng,�
Managing�Director� of�China� and�
Gaurang� Pandya,� Vice� President�
of� International� Department�
joined� the� opening� ceremony� to-
gether�with�PFL�General�Manag-
er�Wilson�Yeung�and�other�senior�
managers.��
During� the� ceremony,�
Steven�Zhou,�Tied�Agency�Head�
of�PFL�delivered� the�opening� re-
marks�by� thanking�all� colleagues�
and�partners�for�their�contribution�
to� the� channel;� he� also� encour-
aged� all� to� join� hand� together� to�
achieve�new�high.
Amid�drum�beats,�two�giant�
lions� mounted� on� the� stage� and�
started� to� dance,� culminating� at�
the�eye-dotting�ceremony,�it�sug-
gest�PFL�as�a�waking�lion�full�of�
power,�bound�to�grow�stronger.��
Three� shareholder� represen-
tatives,� Wilson� Yeung,� Steven�
Zhou� of� Tied� Agency� and�
Haidong� Shen� of� Bancassurance�
jointly� unveiled� the� sales� office.�
While� the� red� ribbon�was�drawn�
and� the� salute� was� fired,� a� roll�
printed� with� "Ambitious� Devel-
opment� and� Booming� Business"�
came�out� from� the�mouth�of� the�
lions,�it�represents�the�best�wish-
es�of� all� guests� for� a� rosy� future�
of�PFL�from�all�guest.�
Wilson,�Bart�and�sharehold-
er�representatives�made�speeches�
in�order;� they�saw� the�day�as�an�
important� moment� for� PFL� as�
this�is�the�first�sales�office�of�the�
company.�With� the�expansion�of�
the�company�and� the� staff,�more�
sales� offices� will� be� opened� to�
meet� customers'� needs.� Both�
shareholders� are� ready� to� pro-
vide�more� support�and� resources�
to� the� company,� they� highly�
praised� and� recognized� the� joint�
efforts�of�the�entire�staff,�and�al-
so�expressed�high�expectation�on�
the� further� development� of� the�
channels.��
To� celebrate� such� a� mean-
ingful� moment,� all� guests�
opened� champagne� of� success�
and� had� a� toast� for� all� partners.�
Steven,� Haidong� and� channel�
representatives� cut� a� cake� to�
mark� the� successful� opening� of�
the� sales� office� and�wished� PFL�
ever-better�performance.�■
Fosun�Pharma�focuses�on�strategic�development�
to�accelerate�international�cooperation